Medicaid
Covered with requirementsWhat you need to qualify
- Age 18 and older
- BMI of 30 or higher
- Prescribed by or in consultation with a specialist
- Diagnosed obstructive sleep apnea (AHI of 15 or higher), with a documented trial of PAP therapy
- Not being used to treat type 1 diabetes
Qualification pathways
You can qualify through any one of these.
Initial Approval — Moderate-to-Severe OSA with Obesity
All of:
- Diagnosis of moderate to severe obstructive sleep apnea (OSA)
- BMI >= 30 kg/m2
- Prescriber documentation of patient's baseline weight
- Prescribed by or in consultation with a neurologist, sleep specialist, or other OSA specialist
- Trial >= 3 months AND failure, contraindication, or intolerance of at least ONE PAP device (APAP, BiPAP, or CPAP)
- Documentation that medication will be used with reduced calorie diet and increased physical activity
- No history of diabetes
- Current A1C < 6.5%
- No personal or family history of medullary thyroid carcinoma (MTC) or MEN 2
- Requested dose does not exceed maximum FDA-approved dose
- Not used in combination with another GLP-1 or dual GLP-1/GIP receptor agonist
Plus any one of:
- AHI/RDI/REI >= 15 events/hour that is predominantly obstructive
- AHI/RDI/REI >= 5 events/hour WITH at least ONE typical OSA symptom (unrefreshing sleep, daytime sleepiness, fatigue, insomnia, awakening with gasping/choking, loud snoring, or witnessed apneas)
Renewal — Continued OSA Treatment
All of:
- Diagnosis of moderate to severe OSA and obesity
- Prescribed by or in consultation with a neurologist, sleep specialist, or other OSA specialist
- Documentation that medication will continue to be used with reduced calorie diet and increased physical activity
- No history of diabetes
- Current A1C < 6.5%
- No personal or family history of medullary thyroid carcinoma (MTC) or MEN 2
- Requested dose does not exceed maximum FDA-approved dose
- Not used in combination with another GLP-1 or dual GLP-1/GIP receptor agonist
Plus any one of:
- Reduction in AHI/RDI/REI by >= 15 events/hour
- Reduction in AHI/RDI/REI by >= 50%
Documentation to bring
- Progress notes documenting confirmed diagnosis of moderate to severe OSA
- AHI/RDI/REI value confirming >= 15 events/hour (predominantly obstructive) OR >= 5 events/hour with at least one typical OSA symptom
- Documentation of BMI >= 30 kg/m2
- Documentation of patient's baseline weight
- Confirmation that prescriber is or has consulted with a neurologist, sleep specialist, or other OSA specialist
- Documentation of >= 3-month trial with failure, contraindication, or intolerance of APAP, BiPAP, or CPAP
- Prescriber attestation that medication will be used with reduced calorie diet and increased physical activity
- Documentation confirming no history of diabetes
- Current A1C result confirming < 6.5%
- Confirmation of no personal or family history of MTC or MEN 2
- For renewal: AHI/RDI/REI result showing >= 15 events/hour reduction or >= 50% reduction
- For renewal: Documentation of >= 5% reduction in baseline body weight OR documentation assessing lifestyle and diet interventions if weight loss goal not met
Quantity limits
- all strengths — 4 pens (2 mL) per 28 days
Approval and renewal
- Initial approval: 6 months
- Renewal: every 6 months
- To renew, the plan looks for at least 5% weight loss from the starting weight and Renewal requires: (1) reduction in AHI/RDI/REI by >=15 events/hour OR >=50%; AND (2) at least 5% reduction in baseline body weight OR documentation assessing lifestyle and diet interventions if weight loss goal not met. Diabetes exclusion (history of diabetes or A1C >=6.5%) is re-verified at renewal. PAP trial requirement is NOT re-checked at renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.
Not covered when
- History of diabetes (any type)
- Current A1C >= 6.5%
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Concomitant use of another GLP-1 or dual GLP-1/GIP receptor agonist
Policy note: This policy is for the OSA indication only. The document excludes patients with a history of diabetes OR current A1C >= 6.5%, making this a non-diabetic OSA population only. PAP device trial (APAP, BiPAP, or CPAP) for >= 3 months with failure, contraindication, or intolerance is required before approval. The AHI lower threshold pathway (AHI >= 5) requires at least one typical OSA symptom. At renewal, the AHI improvement threshold (>=15 events/hour OR >=50% reduction) must be documented. Weight loss of >= 5% from baseline is the renewal weight threshold, but if not met, documentation of lifestyle/diet interventions is an acceptable alternative. Managed by MedImpact Healthcare Systems on behalf of Kentucky Medicaid. Copyright 2025 MedImpact Healthcare Systems, Inc.
verified June 4, 2026 · source: zepbound_pa_criteria.pdf